Bristol-Myers Squibb, Celgene slide following news of delayed deal and psoriasis drug divestment

Shares of Bristol-Myers Squibb plunged Monday after announcing that the target closing date for the proposed acquisition of Celgene has been pushed back and that the deal will include a divestiture of Otezla, a psoriasis drug.